A US cohort study of 543 ovarian cancer patients revealed 37% experienced decreased platelets during niraparib maintenance. Onset typically occurred within 1 month but resolved rapidly with dose adjustments, resulting in low discontinuation rates (16%). However, discontinuations often lacked prior dose modification, indicating management optimization opportunities.